Biocon settles Genentech patent dispute, secures launch dates

Business Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹351.00

prior close

₹353.00

announcement price

After-mkt

timing

Nifty Midcap 150market-0.0%+0.2% vs market

Pharmaceuticals peers, median of 172sector-0.0%+0.2% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Midcap 150 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-1.5

15m

-1.4

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-0.0+0.2-0.0+0.2

Next day

+0.3-0.3+0.6-0.8+1.1

-0.5-0.4-0.1-0.6+0.1

-3.1-1.5-1.6-1.9-1.3

-4.6-2.9-1.7-3.5-1.1

-5.9-3.7-2.2-4.4-1.5

-6.3-4.7-1.7-4.3-2.0

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon has entered a global patent settlement and license agreement with Genentech for Pebrilzo, its biosimilar of Perjeta (Pertuzumab) used for HER2-positive breast cancer. The deal resolves all pending disputes in the US, Canada and other markets. Launch dates: Q1 CY2027 in EU and UK, Q3 CY2028 in the US, and CY2026-2028 in other RoW countries. Other terms are confidential. All launches remain subject to regulatory approval.

Likely market impact

Removes patent overhang and gives Biocon a clear biosimilar launch roadmap in EU, UK, US and RoW markets, though still subject to regulatory clearances.